Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001
Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial
Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
Greg Kunst, CEO of Aurion Biotech, Receives Healthcare Leadership Award from Puget Sound Business Journal
Aurion Biotech Named “Regenerative Therapeutics Company Of The Year
Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial
Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application